CDK13 and cancer: Finally, we leverage paralog-based synthetic lethality to demonstrate that murine and human tumor tissue lacking functional CDK12 is sensitive to CDK13 inhibition and degradation—a finding with future clinical applicability in CDK12-mutant cancers.